At the Endocrinology Outpatient Department (OPD) of Delhi’s Apollo Hospital on a Wednesday, the familiar crowd of elderly patients with diabetes is now joined by well-built men and young women in their late 20s and early 30s. Clutching their reports, these younger patients scroll through their phones or quietly exchange notes on the latest wellness trend — the weight-loss drug. Inside the consultation room, Dr Subhash Wangnoo is now used to hearing a familiar refrain — “Doctor, I started this after seeing it on Instagram”. “This has become the most common opening line in my clinic now,” says the doctor. Over the next few hours, the stories that unfold in this room reveal how medications like Semaglutide and Tirzepatide have moved far beyond their clinical intent. Originally developed as metabolic therapies for diabetes and obesity, they are increasingly being used as quick fixes for rapid, often cosmetic, weight loss — without medical supervision.…